Sanguinaria oral care safety
This article was originally published in The Rose Sheet
Executive Summary
Sanguinaria extract in oral hygiene products "may not be safe or even desirable to use," Boston University Oral and Maxillofacial Pathology Professor Sadru Kabani states in July 21 comments to FDA regarding advance notice of proposed rulemaking on OTC antigingivitis/antiplaque products. Kabani bases comments on observations made clinically and microscopically since 1995, including experience with 15-20 patients who have developed oral leukoplakia and notes, "current research suggests that sanguinaria may have a possible role in the pathogenesis of these oral changes." Research on the ingredient up to the end of 1998 on which FDA based its recommendations "appeared in non-peer reviewed journals based on studies for a short duration of time," Kabani adds. Sanguinaria was included as Category I for safety in the ANPR released in May (1"The Rose Sheet" June 2, 2003, p. 3)...
You may also be interested in...
Antigingivitis/Antiplaque Combination With Other Actives Excluded In ANPR
FDA's advance notice of proposed rulemaking on OTC antigingivitis/antiplaque products excludes the combination of antigingivitis/antiplaque ingredients with other oral health care ingredients. The 1notice was published in the May 29 Federal Register
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.